The Effection Of Specific COX-2 Inhibitors On Plasma Levels Of Endothelin-1 And Calcitonin Gene-related Peptide In Patients With Systemic Lupus Erythematosus

Objective: To investigate the effection of specific COX-2 inhibitors on plasma levels of endothelin-1 and calcitonin gene-related peptide in patients with systemic lupus erythematosus and the relationship between clinical symptom, system suffering and disease activity of SLE.Methods: 65 patients with SLE, whose age ranged from 18 to 60 years old, were evaluated in this study and all fulfilled the American Rheumatism Association 1997 revised criteria for the diagnosis of SLE. According to the Systemic Lupus Erythematosus Disease Activity Index(SLEDAI),39 patients whose SLEDAI≥10 were defined active SLE group, and 26 patients (SLEDAI<10) were defined in inactive SLE group. All patients have been treated according to treatment guides of China Rheumatism Association (2005). The patients of treated group, but controlled group have taken celecoxib (200mg/d) for 3 weeks. The blood plasma ET-1 and CGRP levels of all patients were determine by radio-immunity analysis and ESR, CRP, ANA, ds-DNA, ENA, C3, C4, AnuA, RF, BRt, Urt were measured by others methods respectively before and after treatment lasting for 3 weeks, and then defined SLEDAI.Results: (1) The plasma levels of ET-1 in patients with SLE were significantly increased compare to healthy controls (p<0.05), and in patients with active SLE were significantly higher than those inactive ones (p<0.05). The plasma levels of ET-1 showed no significant differences between inactive patients and healthy controls. (2) The plasma levels of CGRP in patients with SLE were significantly decreased compare to healthy controls (p<0.01), and in patients with active SLE were decreased as compare to inactive patients as well as inactive patients and healthy controls (p<0.05). (3) There were significantly positive correlation between plasma levels of ET-1 with SLEDAI (p<0.01) and negative correlation...